The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase

FEBS Letters

Volumn 586, Issue 1, 2012, Pages 55-59

  Zheng, Xuehua ^a   Zhang, Liping ^a   Zhai, Jing ^a   Chen, Yunyun ^a   Luo, Haibin ^a   Hu, Xiaopeng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Aldose reductase; Crystal structure; Metabolite; Sulindac; Tolmetin

Indexed keywords

ALDEHYDE REDUCTASE; EPALRESTAT; INDOMETACIN; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; TOLMETIN;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

ALDEHYDE REDUCTASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; PROTEIN CONFORMATION; SULINDAC;

EID: 84655167598     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2011.11.023     Document Type: Article

References (38)

1. A. Lione, and A.R. Scialli The developmental toxicity of indomethacin and sulindac Reprod. Toxicol. 9 1995 7 20
2. P. van der Sloot, A. Mizisin, and D. Zochodne Sulindac in established experimental diabetes: a follow-up study Can. J. Neurol. Sci. 22 1995 198 201
3. A. Annapurna, S.R. Challa, G.J. Prakash, and R.K. Viswanath Therapeutic potential of sulindac against ischemia-reperfusion-induced myocardial infarction in diabetic and nondiabetic rats Exp. Clin. Cardiol. 13 2008 66 70 (Pubitemid 351865315)
4. K.M. Krishna, G.S. Gopal, C.R. Chalam, K. Madan, V.K. Kumar, G.J. Prakash, and A. Annapurna The influence of sulindac on diabetic cardiomyopathy: a non-invasive evaluation by Doppler echocardiography in streptozotocin-induced diabetic rats Vascul. Pharmacol. 43 2005 91 100 (Pubitemid 40981937)
5. S.Z. Mansour, D.L. Hatchell, D. Chandler, P. Saloupis, and M.C. Hatchell Reduction of basement membrane thickening in diabetic cat retina by sulindac Invest. Ophthalmol. Vis. Sci. 31 1990 457 463 (Pubitemid 20117060)
6. T.A. Gardiner, H.R. Anderson, T. Degenhardt, S.R. Thorpe, J.W. Baynes, D.B. Archer, and A.W. Stitt Prevention of retinal capillary basement membrane thickening in diabetic dogs by a non-steroidal anti-inflammatory drug Diabetologia 46 2003 1269 1275 (Pubitemid 37214985)
7. Y. Hattori, K. Hashizume, K. Nakajima, Y. Nishimura, M. Naka, and K. Miyanaga The effect of long-term treatment with sulindac on the progression of diabetic retinopathy Curr. Med. Res. Opin. 23 2007 1913 1917 (Pubitemid 47300390)
8. Y.R. Sharma, R.B. Vajpayee, R. Bhatnagar, M. Mohan, R.V. Azad, M. Kumar, and R. Nath Topical sulindac therapy in diabetic senile cataracts: cataract-IV Indian J. Ophthalmol. 37 1989 127 133 (Pubitemid 20250662)
9. K.L. Cohen, and S. Harris Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy Arch. Intern. Med. 147 1987 1442 1444 (Pubitemid 17122120)
10. K. Aida, M. Tawata, H. Shindo, S. Tsukahara, and T. Onaya Effects of Anti-Inflammatory Drugs and ONO-2235 on Lens Aldose Reductase and on Sorbitol Accumulation in Red Blood Cells Yamanashi. Med. 3 1988 47 56
11. I.G. Obrosova, and P.F. Kador Aldose reductase / polyol inhibitors for diabetic retinopathy Curr. Pharm. Biotechnol. 12 2011 373 385
12. R. Ramasamy, and I.J. Goldberg Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model Circ. Res. 106 2010 1449 1458
13. P.J. Oates Aldose reductase inhibitors and diabetic kidney disease Curr. Opin. Investig. Drugs 11 2010 402 417
14. K.E. Schemmel, R.S. Padiyara, and J.J. D'Souza Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review J. Diabetes Complications 24 2010 354 360
15. U.C. Yadav, S.K. Srivastava, and K.V. Ramana Understanding the role of aldose reductase in ocular inflammation Curr. Mol. Med. 10 2010 540 549
16. J. Liu, G. Wen, and D. Cao Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives Recent Pat. Anticancer Drug Discov. 4 2009 246 253
17. D.M. Ratliff, F.J. Martinez, T.J. Vander Jagt, C.M. Schimandle, B. Robinson, L.A. Hunsaker, and D.L. Vander Jagt Inhibition of human aldose and aldehyde reductases by non-steroidal anti-inflammatory drugs Adv. Exp. Med. Biol. 463 1999 493 499
18. D. Brunell, D. Sagher, S. Kesaraju, N. Brot, and H. Weissbach Studies on the metabolism and biological activity of the epimers of sulindac Drug Metab. Dispos. 39 2011 1014 1021
19. L. Richter, L.M. Munter, J. Ness, P.W. Hildebrand, M. Dasari, S. Unterreitmeier, B. Bulic, M. Beyermann, R. Gust, B. Reif, S. Weggen, D. Langosch, and G. Multhaup Amyloid beta 42 peptide (Abeta42)-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization Proc. Natl. Acad. Sci. USA 107 2010 14597 14602
20. Y. Takahashi, I. Hayashi, Y. Tominari, K. Rikimaru, Y. Morohashi, T. Kan, H. Natsugari, T. Fukuyama, T. Tomita, and T. Iwatsubo Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces A beta 42 generation J. Biol. Chem. 278 2003 18664 18670 (Pubitemid 36799494)
21. S.D. Steinbrink, C. Pergola, U. Buhring, S. George, J. Metzner, A.S. Fischer, A.K. Hafner, J.M. Wisniewska, G. Geisslinger, O. Werz, D. Steinhilber, and T.J. Maier Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations Cell. Mol. Life Sci. 67 2010 797 806
22. S. Weggen, J.L. Eriksen, P. Das, S.A. Sagi, R. Wang, C.U. Pietrzik, K.A. Findlay, T.E. Smith, M.P. Murphy, T. Bulter, D.E. Kang, N. Marquez-Sterling, T.E. Golde, and E.H. Koo A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity Nature 414 2001 212 216 (Pubitemid 33051236)
23. 2-terminal kinase 1 Clin. Cancer Res. 6 2000 4136 4141
24. M. Jung, A.F. Wahl, W. Neupert, G. Geisslinger, and P.D. Senter Synthesis and activity of fluorinated derivatives of sulindac sulphide and sulindac sulphone Pharm. Pharmacol. Commun. 6 2000 217 221 (Pubitemid 30337629)
25. M.C. Van Zandt, M.L. Jones, D.E. Gunn, L.S. Geraci, J.H. Jones, D.R. Sawicki, J. Sredy, J.L. Jacot, A.T. Dicioccio, T. Petrova, A. Mitschler, and A.D. Podjarny Discovery of 3-[(4, 5, 7-trifluorobenzothiazol-2-yl)methyl]indole- N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications J. Med. Chem. 48 2005 3141 3152 (Pubitemid 40628034)
26. Collaborative Computational Project, Number 4 The CCP4 suite: programs for protein crystallography Acta Crystallogr. D: Biol. Crystallogr. 50 1994 760 763
27. P.D. Adams, P.V. Afonine, G. Bunkoczi, V.B. Chen, I.W. Davis, N. Echols, J.J. Headd, L.W. Hung, G.J. Kapral, R.W. Grosse-Kunstleve, A.J. McCoy, N.W. Moriarty, R. Oeffner, R.J. Read, D.C. Richardson, J.S. Richardson, T.C. Terwilliger, and P.H. Zwart PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. D: Biol. Crystallogr. 66 2010 213 221
28. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr. D: Biol. Crystallogr. 60 2004 2126 2132 (Pubitemid 41742764)
29. K.M. Bohren, and C.E. Grimshaw The sorbinil trap: a predicted dead-end complex confirms the mechanism of aldose reductase inhibition Biochemistry 39 2000 9967 9974 (Pubitemid 30626847)
30. H. Steuber, M. Zentgraf, A. Podjarny, A. Heine, and G. Klebe High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group J. Mol. Biol. 356 2006 45 56 (Pubitemid 43069726)
31. O. El-Kabbani, C. Darmanin, M. Oka, C. Schulze-Briese, T. Tomizaki, I. Hazemann, A. Mitschler, and A. Podjarny High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor J. Med. Chem. 47 2004 4530 4537 (Pubitemid 39096840)
32. F. Ruiz, I. Hazemann, A. Mitschler, A. Joachimiak, T. Schneider, M. Karplus, and A. Podjarny The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48 Acta Crystallogr. D: Biol. Crystallogr. 60 2004 1347 1354 (Pubitemid 41079730)
33. E.I. Howard, R. Sanishvili, R.E. Cachau, A. Mitschler, B. Chevrier, P. Barth, V. Lamour, M. Van Zandt, E. Sibley, C. Bon, D. Moras, T.R. Schneider, A. Joachimiak, and A. Podjarny Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 Proteins 55 2004 792 804 (Pubitemid 38702939)
34. G.B. McGaughey, M. Gagne, and A.K. Rappe Pi-Stacking interactions Alive and well in proteins. J. Biol. Chem. 273 1998 15458 15463
35. E.A. Salter, A. Wierzbicki, G. Sperl, and W.J. Thompson Molecular modeling study of COX-2 inhibition by diarylheterocycles and sulindac sulfide J. Mol. Struct.-Theochem 549 2001 111 121 (Pubitemid 32705840)
36. N. Okulik, and A.H. Jubert Theoretical study on the, structure and reactive sites of three non-steroidal anti-inflammatory drugs: Ibuprofen, Naproxen and Tolmetin acids J. Mol. Struct.-Theochem 769 2006 135 141
37. C. Koch, A. Heine, and G. Klebe Ligand-induced fit affects binding modes and provokes changes in crystal packing of aldose reductase Biochim. Biophys. Acta 1810 2011 879 887
38. Steuber, H. (2011). An Old NSAID Revisited: Crystal Structure of Aldose Reductase in Complex with Sulindac at 1.0 Supports a Novel Mechanism for its Anticancer and Antiproliferative Effects. ChemMedChem, DOI: 10.1002/cmdc. 201100374.